

Irkutsk State Medical Academy of Continuing Education

Irkutsk Regional Oncology Center

Tactics of treatment in colorectal cancer with metastatic liver disease

R.I. Rasulov




Irkutsk - 2017




structure of cancers in Irkutsk region

for 2016





structure of colorectal cancer of Irkutsk region





tactics of treatment of metastatic liver disease

of the period to 2001

proximal loop colostomy



symptomatic treatment

85,3% - die within the first year
14,7% - survive 1 year
7,9±1,86 mon - average life expectancy

large intestine surgery

- hemicolectomy
- resection of the transverse colon
- sigmoidectomy
- anterior rectal resection
- abdominal-anal resection of the rectal
- abdominal-perineal extirpation of the rectal



± systemic polychemotherapy
(PChTh)

1-year

40,0%

2- year

9,1%

3- year

5,0%

5- year

no


average life expectancy

10,8±1,33 mon



tactics of treatment of metastatic liver disease


period 2001-2005






tactics of treatment in disease one liver lobe

since 2005 till now






CT-volumetry of the liver and metastatic foci





tactics of treatment for bilobate resectable metastatic liver disease


since 2005 till present





tactics of treatment for bilobate non-resectable metastatic liver disease

since 2005 till present





metastatic liver disease while colorectal cancer

volume of operations on the liver

character of metastatic liver disease

liver surgeries

- solitary mts up to 5 cm
- single mts up to 5 cm in one lobe
- single mts to 5 cm in both lobes

marginal mts location - atypical liver resection
Intraparenchymal - ablation of liver mts

- solitary mts over 5 cm

1 segment - segmentectomy
2 segments - bisegmentectomy
3-4 segments - hemihepatectomy

- single mts over 5 cm in one lobe
- multiple mts in one lobe

hemihepatectomy

- single mts up to 5 cm in one lobe
+ single mts more than 5 cm in the second
- single mts up to 5 cm in one lobe
+ multiple mts in the second

marginal resection, ablation of mts of the lobe
with the least lesion and hemihepatectomy of the
lobe with the largest mts lesion



metastatic liver disease while colorectal cancer

volume of operations on the liver

character of metastatic liver damage

liver surgeries

- single mts over 5 cm in both lobes

the volume of operation is variable and only with a residual volume of the liver not less than 30% without cirrhosis and not less than 50% with cirrhosis

- single mts over 5 cm in one lobe
+ multiple mts in the second
- multiple bilobate liver disease

liver surgery is not indicated



right hepatectomy

technical aspect





ablation of liver metastases


technical aspect



ECU-300, Söring, Germany






Cool-tip RF, Valleylab, USA





arterial port setting




technical aspect





hepatic artery chemoembolization


technical aspect





chemoinfusion and chemoembolization regimens

technical aspect



chemoinfusion

systemic PChTh regimens

chemoembolization

I doxorubicin 50 mg
lipiodol 5.0 ml

II doxorubicin 50 mg
microspheres

repeat after 3-4 months



polychemotherapy regimens

technical aspect

~ 50%

leucovorin - 25 mg/m², 1-5 days, in/v

5-fluorouracil - 425 mg/m², 1-5 days., in/v

repeat after 28 days.

~ 25%

oxaliplatinum - 85 mg/m², 1 day, in/v

leucovorin - 25 mg/m², 1,2 days., in/v

5-fluorouracil - 500 mg/m², 1,2 days., in/v

repeat after 14 days.

~ 15%

irinotecan - 125 mg/m²

leucovorin - 25 mg/m²

5-fluorouracil - 500 mg/m²

once in 7 days

~ 10%

other regimens




hemihepatectomy right/left	20
hemihepatectomy + ablation mts + art. port	8
anatomy/atypical liver resection	8
liver resection + ablation mts \pm art. port, CEPVT	18
ablation mts \pm art. port, CEPVT	28
surgery on large intestine + hemihepatectomy \pm ablation mts, art port, CEPVT	212
surgery on large intestine + ablation mts, \pm art port, CEPVT	148
surgery on large intestine +/- art port, CEPVT	130
total	572



long-term survival

period 2005-2012

prospective controlled trial





long-term survival

period 2005-2012

